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Abstract
Purposes Studies investigating self-reported long-term morbidity in childhood cancer survivors (CCS) are using heterogeneous
outcome definitions, which compromises comparability and include (un)treated asymptomatic and symptomatic outcomes. We
generated a Dutch LATER core set of clinically relevant physical outcomes, based on self-reported data. Clinically relevant
outcomes were defined as outcomes associated with clinical symptoms or requiring medical treatment.
Methods First, we generated a draft outcome set based on existing questionnaires embedded in the Childhood Cancer Survivor
Study, British Childhood Cancer Survivor Study, and Dutch LATER study. We added specific outcomes reported by survivors in
the Dutch LATER questionnaire. Second, we selected a list of clinical relevant outcomes by agreement among a Dutch LATER
experts team. Third, we compared the proposed clinically relevant outcomes to the severity grading of the Common Terminology
Criteria for Adverse Events (CTCAE).
Results A core set of 74 self-reported long-term clinically relevant physical morbidity outcomes was established. Comparison to
the CTCAE showed that 36% of these clinically relevant outcomes were missing in the CTCAE.
Implications for Cancer Survivors This proposed core outcome set of clinical relevant outcomes for self-reported data will be used
to investigate the self-reported morbidity in the Dutch LATER study. Furthermore, this Dutch LATER outcome set can be used as
a starting point for international harmonization for long-term outcomes in survivors of childhood cancer.
Keywords Childhood cancer survivors . Long-termmorbidity . Outcome assessment . Outcome definition
Introduction
The vast majority of children diagnosed with cancer nowadays
will achieve long-term survival [1, 2]. Those childhood cancer
survivors (CCS) are a growing, vulnerable group of individuals
who are at risk of developing long-term morbidity due to pre-
vious treatment for cancer in early stages of life. Knowledge on
the burden of long-term morbidity in CCS, its underlying types
of health conditions and its risk factors, has been presented in
various studies during the past decades [3–5].
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In long-term morbidity research in CCS, a broad variety of
outcome assessment methods is used. Long-term morbidity
outcomes can be assessed by self-reporting via questionnaires
[6–24], by medical evaluation during outpatient clinic visits
[25–34] or by linkage with existing registries such as national
hospital discharge registries [35–39]. Authors often include
different types and different numbers of organ systems in their
calculations of physical long-term morbidity [6–39]. Also, in-
cidence or prevalence estimates are often reported without de-
scribingwhich health conditions or organ systemswere includ-
ed in these calculations. Definitions of long-term morbidity
outcomes also vary, for example, authors reporting on cardio-
vascular conditions generally report on heart failure, myocar-
dial infarction, and hypertension, but some also include stroke
as a cardiovascular condition [10, 14, 17, 18, 36]. While many
authors do not grade the severity of the reported long-term
morbidity in CCS, others use the Common Terminology
Criteria for Adverse Events (CTCAE) [40], either in its original
form or an adapted version incorporating specific additional
outcomes that authors considered missing [41–43]. This lack
of uniformity in types of outcomes, outcome definitions, and
outcome grading—even among studies that use similar data
ascertainment methods—limits interpretation, comparability,
and generalizability of studies investigating the burden of
long-term morbidity in CCS. Furthermore, the described out-
comes in current studies include asymptomatic and symptom-
atic outcomes with or without treatment. To get a better insight
in the overall burden for survivors, the Dutch LATER ques-
tionnaire study would like to evaluate only outcomes that are
symptomatic and/or requiring medical treatment.
The aim of this study is to develop a set of self-reported
long-term physical outcomes that are clinically relevant for
CCS, defined as morbidities with clinical symptoms and/or
requiring medical treatment, to investigate the burden of mor-
bidity in the Dutch LATER questionnaire study.
Methods
Development of draft outcomes set based on existing
questionnaires and input from survivors
Three commonly used questionnaires addressing long-term
morbidity in childhood cancer survivors were used for this
article: the Dutch Childhood Oncology Group—Long-Term
Effects After Childhood Cancer (Dutch LATER) study ques-
tionnaire which was used in the Dutch LATER research pro-
gram [44], the Northern American Childhood Cancer Survivor
Study questionnaire [45], and the British Childhood Cancer
Survivor Study questionnaire [46]. See Supplementary
Tables S1–S3 for the respective items. In long-term morbidity
research, the Childhood Cancer Survivor Study questionnaire
was used either in its original form [6–8, 10, 12–15, 18, 20, 22,
24, 47–52] or adapted by authors for their own specific study
[9, 21, 53]. The questionnaires covered multiple dimensions of
late side effects. For this article, we focused on self-reported
physical outcomes, covered by the questionnaire sections on
medical history and health conditions.
The methods of comparing the three long-term morbidity
questionnaires and selection of self-reported long-term phys-
ical outcomes for CCS are summarized in Fig. 1. We con-
densed all outcomes from the three questionnaires into 15
categories. All but two were defined per organ system, i.e.,
conditions of the eye, ear, speech, cardiac, vascular, pulmo-
nary, gastro-intestinal, hepatic, renal and urinary tract, endo-
crine, musculoskeletal, neurologic conditions, and other con-
ditions. In addition, surgical procedures and malignancies
were considered (Supplementary Table S4).We listed the con-
cordances and discordances in outcomes embedded in the
three aforementioned questionnaires.
The draft outcome set consisted of a selection of (concor-
dant and discordant) outcomes. Next, we reviewed all health
conditions that were reported in the open text fields by CCS
participating in the Dutch LATER questionnaire study and
added these outcomes to the draft outcome set by outcome
category. Temporary or self-limiting morbidities, for example,
urinary tract infections, pneumonia, and runner’s knee, were
not considered as potential outcomes due to their transient
nature and were, therefore, removed from the draft outcome
set. Childhood cancer-directed surgeries impacting CCS in
later life, for example, limb amputation which results in a
lifelong disability or removal of an eye which results in life-
long complications, were added to the draft outcome list.
Also, obesity and underweight were added because they were
no self-reported outcome in the aforementioned
questionnaires.
Selection of self-reported long-term physical
outcomes for CCS
The draft outcome set was reviewed in detail by the Dutch
LATER experts team, which comprised a multidisciplinary
team of late effects clinicians (pediatric oncology and medical
oncology), late effects researchers, a pediatric endocrinologist,
and a survivor representative, all of whom are involved in the
late effects research. The experts team focused on health con-
ditions that were relevant for childhood cancer survivors, i.e.,
health conditions that influence their daily life, either by
resulting in symptoms or by requiring medical treatment. A
proposal for a core outcome set was established by agreement
by two authors (N.S. and L.F.), which was discussed by the
experts team in a phone meeting. During this meeting, agree-
ment was established regarding a final core set, containing all
outcomes deemed relevant for survivors.
Subsequently, for each outcome in the core set, definitions
for clinical relevance were established by three authors (N.S.,
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L.F., and L.K.), based on outcome-specific (potential) clinical
symptoms and/or (potential) medical treatment. For obesity
and underweight in adults, clinical relevance was defined ac-
cording to the definitions used by the World Health
Organization. These definitions were discussed by the experts
team by e-mail, until agreement was reached for all clinical
relevance criteria.
Comparison between CTCAE and the new Dutch
LATER core outcome set
The CTCAE, originally developed to score acute treatment
toxicities [40, 54], is commonly used to grade the severity of
outcomes in survivorship studies. This terminology comprises
a 5-point grading scale for many adverse events, which are
defined as unfavorable and unintended signs, symptoms, or
disease, associated with the use of medical treatment. Severity
grades rank from 1 (mild, asymptomatic or mild symptoms;
clinical or diagnostic observations only; intervention not indi-
cated) to 5 (death related to adverse event) [40]. To gain
insight in the agreement between our newly defined outcome
set and CTCAE grading, we added the CTCAE grade based
on version 4.03 corresponding to our outcome definition for
every proposed physical long-term morbidity outcome.
Recently, researchers from the St. Jude Lifetime Cohort
Study (SJLIFE) adjusted the CTCAE criteria to grade long-
term morbidity in their cohort for which data was obtained
during clinical assessment using multiple diagnostic modali-
ties. To get insight in concordance between the CTCAE out-
comes and the Dutch LATER core outcome set, we compared
the different lists of outcomes.
Results
Selection of self-reported long-term physical
outcomes of clinical relevance
The process of selection of self-reported clinically relevant
physical long-term physical outcomes, as displayed in Fig. 1,
Fig. 1 Overview steps followed in the process of development of patient reported outcome list for research for physical long-termmorbidity in childhood
cancer survivors
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resulted in a core outcome set consisting of 74 proposed out-
comes. The experts team decided on re-categorizing surgical
procedures within their respective organ system and did not
consider conditions of speech as clinically relevant. Therefore,
the 15 initial outcome categories were re-categorized into 13
proposed main organ system categories: conditions of the eye,
ear, cardiac, vascular, respiratory, gastro-intestinal,
hepatobiliary tract, renal and urinary tract, endocrine, musculo-
skeletal, nervous system conditions, other conditions, and neo-
plasms (see Table 1).
Agreement between the newly defined core outcome
set and the CTCAE grading
For each outcome, the minimum CTCAE grades that corre-
spond with our criteria for clinical relevance are shown in
Supplementary Table S5. In all, 27 out of 74 (36%) outcomes
cannot be graded according to CTCAE because they are not
present in the CTCAE as a separate entity. This group of
outcomes can be categorized into three subgroups. First, it
comprised certain surgeries of which the LATER experts team
agreed upon clinical relevance (n = 18), because they influ-
ence CCS’s daily life either by having medical consequences
(e.g., splenectomy or organ transplantations) or by having
cosmetic consequences (e.g., eye enucleation or limb ampu-
tation). Second, it comprised blindness and deafness, which
are included in the CTCAE not as a specific outcome but as
grading scale for several specific other eye and ear/nose/throat
outcomes. The LATER experts team agreed that regardless of
the underlying pathophysiological mechanism, blindness and
deafness were both clinical relevant outcomes that should be
included in the core outcome set. Third, specific outcomes that
were not present as separate entities in the CTCAE were re-
ported by CCS in the Dutch LATER questionnaire and were
perceived as clinically relevant by the experts team (n = 7):
aortic aneurysm, liver cirrhosis, tubular dysfunction of the
kidneys, prolactinoma, polycystic ovarian syndrome, under-
weight, and pituitary dysfunction.
Of the remaining 48 conditions, 11 (15%) fulfilled the def-
inition for conditions with a CTCAE grade 3, that is, severe or
medically significant but not immediately life-threatening. For
27 (36%) conditions, our criteria for clinical relevance
corresponded with a CTCAE grade 2, moderate severity. For
nine (12%) conditions (decreased pulmonary function, pro-
teinuria, chronic kidney disease, precocious puberty, diabetes
mellitus, ischemic cerebrovascular accident, transient ische-
mic attack, epilepsy, and headache), it was not possible to
define the corresponding CTCAE grade for our established
clinical relevance criteria, because additional clinical informa-
tion was needed for CTCAE-based grading. Comparison to
the SJLIFE-based grading showed that 34 conditions from our
core set were not present in SJLIFE (46%) and additional
information was needed for grading of 5 conditions (7%). A
total of 23 clinically relevant conditions corresponded with
SJLIFE grade 2 (31%) and two clinically relevant conditions
(adrenal insufficiency and growth hormone deficiency)
corresponded with SJLIFE grade 1 (3%).
Discussion
We present a proposal for a core set of 74 self-reported long-
term physical outcomes of clinical relevance in survivors of
childhood cancer. By comparison of existing survivorship
questionnaires and by reviewing every specific morbidity re-
ported by CCS in the open text fields in our Dutch nationwide
questionnaire study, we followed an innovative method which
focuses on outcomes that are clinically relevant for the survi-
vor, due to the fact that its presence influences daily life. Our
outcome set will be used for investigating the burden of long-
term morbidity in the Dutch LATER questionnaire study. This
set can also be used for international harmonization of a uni-
form core outcome set for long-term morbidity in CCS, to
facilitate worldwide collaboration in late effects research.
Compared with other grading scales used for long-term
morbidity research in CCS, the newly developed Dutch
LATER core outcome set differs on three important key
points. First, this core outcome set was designed with the
single purpose of investigating self-reported long-term mor-
bidity in childhood cancer survivors, by combining existing
questionnaires and outcomes reported by survivors. Second,
we selected outcomes describing morbidity with clinical
symptoms or requiring medical treatment, the so-called clini-
cally relevant outcomes. Third we included outcomes where
the treatment for childhood cancer caused direct damage that
had persistent impact for the survivor also in later life, for
example, limb amputation which results in a lifelong disability
or removal of an eye which results in lifelong complications.
Because the CTCAE criteria were originally designed for
grading acute adverse events during adult cancer trials [54],
the current CTCAE version 4.03 [40] does not cover the com-
plete spectrum of long-term morbidity that CCS might en-
counter [42]. Several authors have already stated that relevant
outcomes were missing for CCS and use adapted versions
[41–43]. Comparison of our core set of long-term self-report-
ed physical outcomes to the commonly used CTCAE showed
that 36% of the outcomes were not present in the CTCAE.
Moreover, CTCAE does not incorporate self-reported data to
assess long-term morbidity [42]. For nine out of the 48 con-
ditions that were present in the CTCAE, we could not perform
severity grading because detailed additional clinical informa-
tion was needed for appropriate grading, which was not avail-
able from current questionnaires and is often too complicated
to directly ask patients in a questionnaire. Although often only
health conditions grade 3 and higher are included when study-
ing severe physical long-term morbidity in CCS, our results
669J Cancer Surviv  (2020) 14:666–676
Table 1 Core set of self-reported long-term physical outcomes of clinical relevance for childhood cancer survivors
Self-reported long-term
physical outcome
Definition of clinical relevance
Eye disorders Cataract Cataract of at least one eye treated with surgery
Blindness Blindness of at least one eye
Eye removal Status after removal of at least one eye
Ear Hearing loss Hearing loss of at least one ear, requiring a hearing aid
conditions Deafness Deafness of at least one ear
Cardiac conditions Heart failure Heart failure with clinical symptoms, with at least one of the following criteria:
1. Requiring medication (ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists,
aldosterone receptor antagonists, diuretics, angiotensin II blockers, digoxin)
2. Requiring devices (CRT-P or CRT-D, pacemaker, ICD, LVAP, cardiac reduction surgery)
Ischemia Cardiac ischemia with clinical symptoms requiring intervention (angioplasty, stent, coronary
bypass graft)
Pericarditis Pericarditis with clinical symptoms, with at least one of the following criteria:
1. Life-threatening consequences (hemodynamic comprise, tamponade)2. Requiring surgical
intervention (pericardiectomy)
Valvular disease Valvular disease with clinical symptoms, with at least one of the following criteria:
1. Requiring medication (ACE inhibitors, calcium channel blockers, beta-blockers, enalapril,
diuretics, digoxin)
2. Requiring valve replacement or valvuloplasty
Arrhythmia Arrhythmia with clinical symptoms, with at least one of the following criteria:
1. Requiring medication (beta-blockers, digoxin, calcium channel blockers, amiodarone, sotalol,
flecainide, propafenone, electrolytes, anti-thrombines, anti-platelets, N-3 fatty acid and lipids)
2. Requiring device or surgical intervention (ICD, pacemaker, CRT-P, CRT-D, ablation,
antiarrhythmic surgery, cardioversion)
Heart transplantation Status after heart transplantation
Vascular conditions Hypertension Hypertension, requiring antihypertensive medication (ACE inhibitors, beta blockers, diuretics,
calcium antagonists, angiotensin II antagonists, alfa blockers)
Thrombosis Thrombosis or a thromboembolic event, with at least one of the following criteria:
1. Requiring chronic treatment with antithrombotic agents
2. Requiring surgical intervention
Aneurysm The presence of an aneurysm (confirmed by medical imaging), requiring surgical intervention
Respiratory conditions Obstructive pulmonary
disease
Pulmonary obstructive disease (i.e., asthma, COPD, chronic bronchitis), with clinical symptoms,
with at least one of the following criteria:
1. Requiring chronic medication (beclometason, fluticasone proprionate, ciclesonide, salmeterol,
beclomethasone/formoterol, budesonide/formoterol, salmeterol/estril, montelukast)
2. Requiring chronic oxygen treatment
*Only intermittent therapy with acute bronchodilators is not defined as clinically relevant
Decreased pulmonary
function
Decreased pulmonary function confirmed by spirometry function, which results in limitations in
daily life on participation level (i.e., due to the pulmonary condition unable to function in
work, hobbies, household, or social circumstances)
*Asymptomatic decreased lung function without symptoms detected during routine screening is
not defined as clinically relevant
Pulmonary resection Status after surgery to remove (part of a) lung after which symptoms of decreased pulmonary
function are present
Pulmonary transplantation Transplantation of one or more lungs after which symptoms of decreased pulmonary function are
present
Other pulmonary conditions Other pulmonary conditions (including bullae, pulmonary edema, pleuritis) with clinical
symptoms, confirmed by clinical evaluation, with at least one of the following criteria:
1. Requiring medical treatment with medication or surgery
2. Resulting in limitations in daily life on participation level (due to the pulmonary condition
unable to function in work, hobbies, household or social circumstances)
Gastro-intestinal Gastroesophageal reflux
disease
Gastroesophageal reflux disease, with clinical symptoms, requiring anti acid medication
Inflammatory bowel disease Inflammatory bowel disease (i.e., Crohn and Colitis ulcerosa) with clinical symptoms, with at
least one of the following criteria:
1. Requiring treatment with immunosuppressive medication
2. Requiring surgical intervention




Definition of clinical relevance
Other gastrointestinal
conditions
Gastro-intestinal health conditions, not otherwise specified, with clinical symptoms, causing
mechanical problems (i.e., adhesions, ileus, stenosis, stoma), with at least one of the following
criteria:
1. Requiring chronic tube feeding
2. Requiring chronic total parenteral feeding
3. Requiring surgical intervention
4. The presence of a stoma
5. The removal of (part of the) jaw
Hepatobiliary
conditions
Hepatitis Chronic infection with hepatitis B or C, with at least one of the following criteria:
1. Requiring at least one of the listed medication (interferon or antiviral medication)
2. Resulting in liver cirrhosis
Hemochromatosis Hemochromatosis (iron overload), with clinical symptoms, with at least one of the following
criteria:
1. Requiring treatment with phlebotomy or erythrocytopheresis
2. Requiring iron lowering medication
Liver cirrhosis Cirrhosis of the liver with clinical symptoms
Liver transplantation Status after liver transplantation
Cholecystectomy Status after cholecystectomy
Renal and urinary tract Tubular dysfunction The presence of renal tubular dysfunction with clinical symptoms, resulting in electrolyte
imbalance requiring medication
conditions Proteinuria Proteinuria confirmed by urine analysis, requiring treatment with medication (ACE inhibitors,
thiazide diuretics)
Chronic kidney disease Renal insufficiency with clinical symptoms, requiring medical treatment with at least one of the
following:
1. Antihypertensive drugs (ACE inhibitors, angiotensin II antagonists, diuretics)
2. Medication for proteinuria (ACE inhibitors or thiazide diuretics)
3. Medication for the prevention of cardiovascular complications (statins)
4. Medication for anemia (EPO)
5. Medication for osteodystrophia (phosphate binding medicine, active vitamin D)
6. Medication for electrolyte deficiencies/tubular dysfunction
7. Dialysis
8. Renal transplantation
Urinary tract obstruction Urinary tract obstruction with clinical symptoms, requiring surgical intervention
Nephrectomy Status after the removal of at least one kidney
Renal transplantation Status after transplantation of one (or more) kidney(s)
Other conditions of kidney
and urinary tract
Other conditions of kidney and urinary tract with clinical symptoms, including:
1. The presence of an urine stoma
2. Incontinence, requiring surgical intervention
3. The need for structural catheterization
4. Dialysis
5. Removal of bladder
6. Elevated uric acid treated with chronic medication
Endocrine conditions Adrenal insufficiencyB Adrenal insufficiency with clinical symptoms and confirmed by laboratory testing, requiring
hormonal treatment (glucocorticoids, mineralocorticoids)
Hypercortisolism Hypercortisolism (Cushing’s disease) with clinical symptoms and confirmed by laboratory
testing, with at least one of the following criteria:
1. Requiring surgical intervention
2. Requiring radiation therapy
3. Requiring post-treatment substitution therapy (hydrocortisone)
HypothyroidismB Hypothyroidism with clinical symptoms and confirmed by laboratory testing requiring treatment
with chronic medication (levothyroxine)
Hyperthyroidism Hyperthyroidismwith clinical symptoms and confirmed by laboratory testing, with at least one of
the following criteria:
1. Requiring iodine treatment (radioactive)
2. Requiring surgical intervention (i.e., (hemi)thyroidectomy)




Definition of clinical relevance
3. Requiring medication (i.e., thyreostatics or thyroid suppletion therapy for iatrogenic
hypothyroidism)
Estrogen deficiencyB Estrogen deficiency with clinical symptoms and confirmed by laboratory testing, with at least one
of the following criteria:
1. Requiring treatment with transdermal estrogen
2. Requiring chronic medication (oral estrogen)





Growth hormone deficiency with clinical symptoms and confirmed by laboratory testing, with at
least one of the following criteria:
1. Requiring medical treatment with growth hormone
2. For which growth hormone treatment was indicated, but the treating physician and/or parents
decided not to start this treatment because of medical contra-indications
Hypoparathyroidism Hypoparathyroidism with clinical symptoms and confirmed by laboratory testing, with at least
one of the following criteria:
1. Requiring calcium suppletion
2. Requiring active vitamin D3 (calcitriol or etalpha)
Hyperparathyroidism Hyperparathyroidism with clinical symptoms and confirmed by laboratory testing, requiring
surgical intervention
Prolactinoma Prolactinomawith clinical symptoms and confirmed by laboratory testing, with at least one of the
following criteria:
1. Requiring treatment with dopamine agonists
2. Requiring surgical treatment
Polycystic ovarian
syndrome
The presence of polycystic ovarian syndrome with clinical symptoms, confirmed by imaging
Precocious puberty Early puberty, that has been, or is currently treated with medication (puberty inhibiting medicine,
i.e., GnRH analogues)
Pubertas tarda Late puberty, that has been or is currently treated with medication (sex steroids)
Pituitary deficiency Pituitary deficiency, with clinical symptoms and confirmed by laboratory testing, with at least one
of the following criteria:
1. Requiring growth hormone treatment
2. Requiring thyroid hormone treatment
3. Requiring hydrocortisone treatment
4. Requiring sex hormone treatment
5. Requiring desmopressin treatment
Pituitary surgery Status after surgery to the pituitary gland
Obesity The presence of obesity according to the World Health Organization’s standardized definition of
obesity for adults: BMI > 30, or for children > + 2 SDS in corrected for age and sex according
to Dutch normative dataA
Underweight The presence of underweight according to the World Health Organization’s standardized
definition of underweight for adults: BMI < 18.5, or for children < − 2 SDS corrected for age
and sex according to Dutch normative dataA
Diabetes mellitus Diabetes mellitus with confirmed by laboratory testing with at least one of the following criteria:
1. Requiring treatment with oral antidiabetic agents
2. Requiring treatment with intramuscular or intravenous insulin
Diabetes insipidusB Diabetes insipidus with clinical symptoms and confirmed by laboratory testing, requiring
treatment with medication (desmopressin)
Thyroidectomy Status after (partial) thyroidectomy, after which medication use (levothyroxine) is required
Adrenal gland removal Status after the removal of one or two adrenal gland(s)
Ovariectomy Status after the removal of one or more ovaria





Intracranial hemorrhage with clinical symptoms and confirmed by imaging, with at least one of
the following criteria:
1. Requiring surgical intervention
2. Requiring medication (antihypertensive drugs)
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show that many grade 2 conditions will have consequences for
a survivor because of symptoms or needed treatment. From
our core outcome set, up to 27 clinically relevant outcomes
corresponded with CTCAE grade 2, for example, several en-
docrine deficiencies that require chronic medication use, and
would have been missed in such studies. Comparison to the
SJLIFE adapted CTCAE for grading of clinically ascertained
data showed that more of our core outcomes were missing and
that 24 clinically relevant conditions corresponded to grade 2
or even grade 1. Hence, our results support previous authors,
concluding that the CTCAE in its current form is not optimal
to grade severity of (self-reported) long-term physical morbid-
ity outcomes for CCS [41–43]. To our knowledge, this is the
first comprehensive proposal to define a core outcome set for
self-reported long-term physical outcomes in CCS. A strength
of this study is that we focused on clinical relevance for CCSA
and a limitation is that we were not yet able to incorporate the




Definition of clinical relevance
Cerebrovascular accident—
ischemic
Intracerebral infarction with clinical symptoms and confirmed by imaging, requiring treatment
with medication (acetylsalicylic acid, dipyridamole, statins, or antihypertensive agents)
Transient ischemic attack The presence of a transient ischemic attack (duration < 24 h) with clinical symptoms, requiring
treatment with medication (acetylsalicylic acid, dipyridamole, statins, or antihypertensive
agents)
Epilepsy Epilepsy with clinical symptoms and confirmed by electro-encephalography, requiring treatment
with medication (carbamazepine, lamotrigine, levetiracetam, oxcarbezepine, valproate,
clonazepam, phenytoin, gabapentin, lacosamide, perampanel, pregabalin, topiramate,
zonisamide, clonazepam)
Headache Headache (migraine, cluster headache) resulting in clinical symptoms treated with at least one of
the following criteria:
1. Requiring treatment with beta blockers, anti-epileptic medication, flinarizine, pizotifen,
methysergide, or candesartan (migraine)
2. Requiring treatment with verapamil, lithium carbonate, methysergide, pizotifen, ergotamine, or
prednisone (cluster headache)
Hydrocephalus The presence of hydrocephalus, requiring surgical intervention
Other neurological
conditions
The presence of other neurologic conditions, with clinical symptoms, including facialis paresis,
spinal cord injury, (spastic) paresis, loss of strength, disturbance of equilibrium, coordination
problems, vertigo, acquired brain injury, tremor, parkinsonism, ataxia)
Musculoskeletal
conditions
Amputation Status after the amputation of a (part of a) limb, excluding fingers and toes
Deformities The presence of at least one of the following major deformities (scoliosis, kyphosis, lordosis, or
spondylolisthesis) with clinical symptoms
Osteoporosis Osteoporosis confirmed with a DEXA scan, requiring treatment with chronic medication
(bisphosphonates, estrogen receptor modulators, or parathyroid hormone)
Other musculoskeletal
conditions
At least one of the following conditions with clinical symptoms: arthritis (bacterial, gout,
reactive, rheumatoid arthritis), arthrosis, osteonecrosis, epiphysiolysis, with at least one of the
following criteria:
1. Requiring medication (allopurinol, benzbromaron, leflunomide, methotrexate, sulfasalazine,
infliximab, adalimumab, etanercept, certolizumab, anti-IL1, anti-CD80, anti-CD86,
aurothiomalaat, ciclosporin, hydroxychloroquinine, cyclophosphamide)
2. Requiring therapy using intra-articular injection(s)
3. Requiring joint replacement surgery
4. Requiring arthrodesis surgery
Neoplasms Malignant neoplasms Malignant neoplasms of any kind
Other conditions Dermatological conditions Dermatological conditions with clinical symptoms and that require systematic treatment
Hysterectomy Status after the removal of the uterus
Prostatectomy Status after the removal of the prostate
Mastectomy Status after the removal of one or more breast(s)
Splenectomy Status after splenectomy
A In this study we used Dutch population-based normative data for children below 18 years. For international harmonization, we recommend using Child
Growth Standards from the World Health Organization
BWhen this hormonal deficiency is the result of pituitary dysfunction, it is categorized separately as “pituitary deficiency”
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of future research. Also, because the purpose of this core out-
come set was facilitating the investigation of physical long-
term morbidity in the Dutch LATER cohort, the proposed
outcome definitions reflect the agreement among the Dutch
LATER experts team only. To overcome any subjectivity in
outcomes used by various childhood cancer survivorship re-
search groups, we advocate international harmonization of a
core outcome set for physical long-term morbidity in child-
hood cancer survivors. A uniform global core outcome set is
highly needed to enable comparison of future long-term mor-
bidity studies, to uniformly evaluate survivorship care and to
facilitate collaboration within survivorship research. The
International Guideline Harmonization Group [55] started an
initiative to develop a harmonized outcome set by a Delphi
method. This will facilitate international collaboration and da-
ta pooling.
In conclusion, we propose a Dutch LATER core set of self-
reported long-term physical outcomes of clinical relevance for
CCS that will be used to investigate the burden of long-term
morbidity in childhood cancer survivors from the Dutch
LATER questionnaire study.We advocate to start international
discussion and research to harmonize long-term physical mor-
bidity outcomes that are clinically relevant for CCS.
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